Immetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases
Immetas Therapeutics and GC Biopharma today announced that they have entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases.
- Immetas Therapeutics and GC Biopharma today announced that they have entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases.
- The collaboration combines Immetas’ proprietary platform for modulating innate immune pathways with GC Biopharma’s messenger RNA (mRNA) therapeutic and lipid nanoparticle (LNP) delivery platforms.
- Immetas has generated a comprehensive toolbox to modulate inflammasome activity by targeting multiple pathway mediators with various modalities.
- GC Biopharma has selected mRNA as the new development platform and has been conducting related research since 2017.